Longeveron (LGVN) Total Debt (2021 - 2023)

Longeveron's (LGVN) quarterly Total Debt came in at $586000.0 in Q3 2023, up 1.38% quarter-over-quarter from $578000.0 in Q2 2023.

Longeveron (LGVN) Total Debt (2021 - 2023) Analysis & Trends

Longeveron's Total Debt history runs 3 years deep, the most recent figure standing at $586000.0 for Q3 2023.

  • On a quarterly basis, Total Debt changed N/A year-over-year to $586000.0 in Q3 2023; TTM through Sep 2023 was $586000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $564000.0, up 5.03% from the prior year.
  • Total Debt advanced to $586000.0 in Q3 2023 per LGVN's latest filing, from $578000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $586000.0 in Q3 2023 and bottomed at $537000.0 in Q4 2021.
  • The 3-year median for Total Debt is $571000.0 (2023), against an average of $567200.0.
  • Biggest YoY gain for Total Debt was 5.03% in 2022; the steepest drop was 5.03% in 2022.
  • Year by year, Total Debt stood at $537000.0 in 2021, then advanced by 5.03% to $564000.0 in 2022, then advanced by 3.9% to $586000.0 in 2023.
  • Per Business Quant, the three latest LGVN Total Debt figures stand at $586000.0 (Q3 2023), $578000.0 (Q2 2023), and $571000.0 (Q1 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 959.06 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2023 586,000.00
Jun 30, 2023 578,000.00
Mar 31, 2023 571,000.00
Dec 31, 2022 564,000.00
Dec 31, 2021 537,000.00